AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The formation of such a heterochromatin region, though not its maintenance, is Dicer-dependent, presumably because Dicer is required to generate the initial complement of siRNAs that target subsequent transcripts. Heterochromatin maintenance has been suggested to function as a self-reinforcing feedback loop, as new siRNAs are formed from the occasional nascent transcripts by RdRP for incorporation into local RITS complexes. The relevance of observations from fission yeast mating-type regions and centromeres to mammals is not clear, as heterochromatin maintenance in mammalian cells may be independent of the components of the RNAi pathway.
coli bacteria stores proteins and pyrophosphates in its periplasmic membrane until either are needed within the cell. Recent advancement in phosphoproteomic identification has resulted in the discoveries of countless phosphorylation sites in proteins. This required an integrative medium for accessible data in which known phosphorylation sites of proteins are organized. A curated database of dbPAF was created, containing known phosphorylation sites in H. sapiens, M. musculus, R. norvegicus, D. melanogaster, C. elegans, S. pombe and S. cerevisiae. The database currently holds 294,370 non-redundant phosphorylation sites of 40,432 proteins. Other tools of phosphorylation prediction in proteins include NetPhos for eukaryotes, NetPhosBac for bacteria, and ViralPhos for viruses.
=== Significant dates === According to legend, the coffee plant was discovered in Ethiopia by a goat herder named Kaldi around 850 AD, who observed increased physical activity in his goats after they consumed coffee beans. First cultivation in India (Chikmagalur) – 1600 First cultivation in Europe – 1616 First cultivation in Java – 1699 First cultivation in Caribbean (Cuba, Hispaniola, Jamaica, Puerto Rico) – 1715–1730 First cultivation in Dutch East Indies – 1720 First cultivation in South America – 1730 Roasted beans first sold on retail market (Pittsburgh) – 1865 Various coffee extracts, and powdered instant coffee, developed in the late 19th century
Gaddafi was later infuriated when Egypt and Syria planned the Yom Kippur War against Israel without consulting him and was angered when Egypt conceded to peace talks rather than continuing the war. Gaddafi became openly hostile to Egypt's leader, calling for Sadat's overthrow. When Sudanese President Gaafar Nimeiry took Sadat's side, Gaddafi also spoke out against him, encouraging the Sudan People's Liberation Army's attempt to overthrow Nimeiry. In 1974, Gaddafi released Abdul-Aziz Shennib, a commander under King Idris, from prison and appointed him Libyan ambassador to Jordan. Shennib had attended the Royal Military Academy Sandhurst with King Hussein of Jordan and was tasked by Gaddafi with Hussein's assassination. Shennib instead informed Hussein of the plot and defected to Jordan. Relations with Syria also soured over the events in the Lebanese Civil War. Initially, both Libya and Syria had contributed troops to the Arab League's peacekeeping force, although after the Syrian army attacked the Lebanese National Movement, Gaddafi openly accused Syrian President Hafez al-Assad of "national treason"; he was the only Arab leader to criticize Syria's actions. In late 1972 and early 1973, Libya invaded Chad to annex the uranium-rich Aouzou Strip. Intent on propagating Islam, in 1973 Gaddafi founded the Islamic Call Society, which had opened 132 centres across Africa within a decade. In 1973 he converted Gabonese President Omar Bongo, an action which he repeated three years later with Jean-Bédel Bokassa, president of the Central African Republic.
==== Gene gun delivery and biolistics ==== Gene gun delivery/Biolistics has been an attractive method for gene delivery due to its non-viral properties, and in addition to viral transduction, is one of the most common methods. This allows for less adverse immune responses and a smaller chance of viral infection compared to viral-based transfer methods. Rather than using a viral vector, this technique utilizes physical methods, specifically using helium propulsion to deliver transformation vectors. Gene gun delivery has been traditionally used for the generation of transgenic plants as it has been able to efficiently and effectively penetrate the cell walls. More recently, this technique has been successful in animal cells that cannot tolerate high-level bombardment, where instead DNA gold particles are delivered at lower helium pressure. This method has been successfully used both in vitro and in vivo.
Sources: en.wikipedia.org
==== Metabolism ==== DMT is primarily metabolized by monoamine oxidase A (MAO-A) (>90%) into indole-3-acetic acid (IAA) and to a much lesser extent in the liver by CYP2D6 and CYP2C19. When taken intravenously, DMT is primarily metabolized by MAO-A in the circulatory system and brain. When smoked, a more substantial fraction (possibly as high as 10–20%) is metabolized in the liver by CYP2D6 and CYP2C19.
In trying to uncover the intermediate stages of abiogenesis mentioned by Bernal, Sidney Fox in the 1950s and 1960s studied the spontaneous formation of peptide structures under plausibly early Earth conditions. In one of his experiments, he allowed amino acids to dry out as if puddled in a warm, dry spot in prebiotic conditions: In an experiment to set suitable conditions for life to form, Fox collected volcanic material from a cinder cone in Hawaii. He discovered that the temperature was over 100 °C just 4 inches (100 mm) beneath the surface of the cinder cone, and suggested that this might have been the environment in which life was created—molecules could have formed and then been washed through the loose volcanic ash into the sea. He placed lumps of lava over amino acids derived from methane, ammonia and water, sterilized all materials, and baked the lava over the amino acids for a few hours in a glass oven. A brown, sticky substance formed over the surface, and when the lava was drenched in sterilized water, a thick, brown liquid leached out. He found that, as they dried, the amino acids formed long, often cross-linked, thread-like, submicroscopic polypeptides.
On December 14, 2008, Muntadhar al-Zaidi, an Iraqi journalist, threw both of his shoes at Bush during a press conference in Baghdad. Bush was not injured, having ducked the pair of shoes. However, White House press secretary Dana Perino received a bruise on her face after being hit by a microphone boom knocked over by security. Al-Zaidi received a three-year prison sentence which was reduced to one year. On September 15, 2009, he was released early for good behavior.
Missouri and, before the abolition of capital punishment, Delaware, use or used a lethal injection machine designed by Massachusetts-based Fred A. Leuchter consisting of two components: the delivery module and the control module. The delivery module is in the execution chamber. It must be preloaded with the proper chemicals and operate with the timing of the dosage. The controller module is in the control room. This section is the portion that officially starts the procedure. The operation is done by first arming the machine and then having station members simultaneously press each of their buttons on the panel to activate the delivery. The computer then deletes the identity of the person who actually started the syringes, so the participants are not aware whether their syringe contained saline or one of the drugs necessary for execution (to assuage guilt in a manner similar to the blank cartridge in execution by firing squad). The delivery module has eight syringes. The end syringes (i.e., syringes 7 and 8) containing saline, syringes 2, 4 and 6 containing the lethal drugs for the main line and syringes 1, 3 and 5 containing the injections for the backup line. The system was used in New Jersey before the abolition of the death penalty in 2007. Illinois previously used the computer, and Missouri and Delaware use the manual injection switch on the delivery panel. Eleven states have switched, or have stated their intention to switch, to a one-drug lethal injection protocol. A one-drug method is using the single drug sodium thiopental to execute someone.
The best-known brands labelled as cider are Golden Cap, Fizz, and Upcider. They typically contain 4.5–4.7% volume of alcohol. Virtually all Finnish "cider" is produced from fermented apple (or pear) juice concentrate mixed with water and is not cider as per the traditional description of the drink. Flavoured ciders, available in a large selection, are very popular and widely available in stores, with a variety of flavours ranging from forest berry to rhubarb and vanilla.
Sources: en.wikipedia.org
A Scatchard plot (Rosenthal plot) can be used to show radioligand affinity. In this type of plot, the ratio of Bound/Free radioligand is plotted against the Bound radioligand. The slope of the line is equal to the negative reciprocal of the affinity constant (K). The intercept of the line with the X axis is an estimate of Bmax. The Scatchard plot can be standardized against an appropriate reference so that there can be a direct comparison of receptor density in different studies and tissues. This sample plot indicates that the radioligand binds with a single affinity. If the ligand were to have bound to multiple sites that have differing radioligand affinities, then the Scatchard plot would have shown a concave line instead.
Secondary U.S. sanctions prohibit any trading in U.S. dollars and prevent trade with a country, individuals, or organizations under the U.S. sanctions regime, affecting non-U.S. persons even where no U.S.-jurisdictional nexus existed. Primary sanctions, by contrast, restrict only U.S. companies, institutions, and citizens from doing business with sanctioned countries or entities. According to Rawi Abdelal, secondary sanctions often create friction between the U.S. and Europe because they reflect U.S. interference in the affairs and interests of the European Union (EU), and their increasing use is perceived in the EU as a violation of national and EU sovereignty. Secondary sanctions imposed on Iran and Russia are central to these tensions. Abdelal also argues that the U.S.'s overuse of sanctions risks gradual isolation and the continuing decline of U.S. influence in an emerging multipolar world. In June 2025, a majority of U.S. senators supported secondary sanctions against Russia that would impose 500% tariffs on countries that buy Russian oil, natural gas, uranium, and other exports. On July 31, 2025, the U.S. announced its first "secondary tariff," targeting India to penalize its trade with Russia, with Indian exports facing an extra 25% tariff beginning August 27, 2025.
Through this mechanism the liver may be restored to its original state, scar-free. However, despite nearly 80 years of research on liver regeneration much debate still surrounds the exact mechanisms by which the process occurs. Another example of spontaneous regeneration endometrial lining of the uterus after menses during reproductive years. Endometrial glands from a basal layer of the uterine wall can regenerate the functional layer without fibrosis or scarring. By 2014 the kidney had been found to have the ability to regenerate. Following removal or incapacitation of one kidney the other may double in size in order to counteract the loss of the other kidney. This is known a compensatory growth. Induced regeneration stimulated by an outside source of a "non-regenerative" organ. In humans is for therapeutic use. Induced regeneration is being trialled to replace organ transplants as issues such as rejection, lack of donors, and scarring would be eliminated. The table below details some of the tissues in which induced regeneration has been attempted;
Most commonly, depot injections are designed to have a duration of 2–4 weeks of action, however the pharmacokinetics of a specific formulation vary. Absorption and metabolism can both be affected by modifying the drug itself (for example, by attaching a functional group) or by the formulation of the product (examples are oil or microsphere preparations). Repeated administration of depot injections can lead to a half life over one month (as in some preparations of fluphenazine), but this can be variable in different patients. Hormonal depot injections of estradiol can last anywhere from one week to over one month. Medroxyprogesterone acetate is available as a depot injection which is injected once every three months to provide continuous hormonal contraception and releases for up to nine months after injection.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.